The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D
3
ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.
The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D
3
ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.
(DE) Die vorliegende Erfindung betrifft das Fumarsäuresalz von 2-3-[4-(2-t-Butyl-6- trifluormethylpyrimidin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol sowie pharmazeutische Mittel, welche dieses Salz enthalten. Das Salz ist zur Behandlung von Erkrankungen, die auf Dopamin-D3-Liganden ansprechen, brauchbar. Es besitzt erhöhte Stabilität bei niedrigem pH und ist daher zur oralen Applikation besonders geeignet.(EN) The invention relates to the fumaric acid salt from 2-3-[4-(2-T-butyl-6- trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol and to pharmaceutical agents containing said salt. The salt can be used for treating diseases which respond to dopamine-D3 ligands. It is very stable at a low pH and is therefore especially suitable for oral administration.(FR) L'invention concerne un acide fumarique de 2-3-(4-(2-t-Butyl-6- trifluorométhylpyrimidin-4-yl) pipérazin-1-yl] propylmercapto} pyrimidin-4-ol et des substances pharmaceutiques contenant ce sel. Ce sel peut être utilisé pour le traitement de maladies qui répondent aux ligands dopamine-D3. Grâce à une stabilité améliorée pour un faible pH, ce sel convient particulièrement à une administration par voie orale.